Cytogen is a global leader in liquid biopsy platforms, offering innovative solutions for cancer diagnosis and treatment. Established in 2010, Cytogen developed a unique chip that captures live Circulating Tumor Cells (CTCs), paving the way for advancements in cancer research. Their fully automated liquid biopsy platform allows for efficient CTC isolation, detection, and analysis.

This breakthrough technology has led to collaborations with prestigious research institutes, top-tier hospitals, and leading pharmaceutical companies worldwide. Cytogen's products and services encompass various areas, including cancer drug development, cancer drug monitoring, companion diagnostics, and clinical research. They also offer CLIA preclinical xenograft models and cutting-edge liquid biopsy equipment.

Moreover, Cytogen provides invaluable support to cancer patients and their families through their commitment to public goods and sound business ethics. Based in Seoul, Cytogen continues to drive innovation through ongoing research and development efforts, aiming to become the world's foremost biomedical engineering company. With a global network and unwavering dedication, Cytogen strives to revolutionize cancer treatment and improve patient outcomes worldwide